Livsmed Inc.
KKRX:49100038,000.00
KRW
-950.00
(-2.44%)
ISIN
KR7491000006
Return %
Stock
S&P 500
1Y
- -
14.39
3Y
- -
81.42
5Y
- -
68.62
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Jeong-Ju Lee
- Full Time Employees
- 334
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Seongnam-si South Korea
- IPO Date
- Dec 24, 2025
- Website
- livsmed.com
- Similar Companies
- Business
- LivsMed Inc. is a South Korea-based medical technology company specializing in the design, development, and commercialization of advanced minimally invasive surgical devices and handheld articulating laparoscopic instrumentation. The company engineers ergonomic, multi-jointed surgical tools that replicate the natural dexterity, degrees of freedom, and tactile feedback of open and robotic surgery within standard laparoscopic procedures. LivsMed operates across specialized medical product portfolios comprising the ArtiSential series of single-use, 360-degree articulating handheld laparoscopic instruments, including articulating needle holders, articulating bipolar Maryland dissectors, precise and fenestrated grasping forceps, articulating scissors, and clip appliers; the ArtiSential 5 line of 5-millimeter diameter articulating instruments designed for reduced-port and pediatric applications; articulating monopolar energy devices, including hook and spatula dissectors; the ArtiSeal 90-degree articulating advanced bipolar vessel sealing system; and the proprietary STARK surgical robotic platform currently under development for remote telesurgery and robot-assisted interventions. The company markets its products to public and private hospitals, academic medical centers, and ambulatory surgery centers across general surgery, urology, gynecology, colorectal surgery, and thoracic surgery disciplines. Founded in 2011 and headquartered in Seongnam-si, Gyeonggi-do, South Korea, LivsMed conducts global operations through direct subsidiaries including LivsMed USA Inc. in San Diego, California, and LivsMed Germany GmbH in Bochum, Germany, supported by regional business units in Japan and authorized distribution networks servicing more than 70 countries worldwide. Recent company developments include the successful completion of its initial public offering on the KOSDAQ market under ticker KRX:491000, raising approximately 135.9 billion Korean won to fund integrated manufacturing facilities and next-generation surgical robotic research; strategic commercial partnerships, including a multi-year distribution agreement with Genesis MedTech for mainland China market entry and channel expansion in Japan; broadened international regulatory clearances, encompassing expanded U.S. Food and Drug Administration 510(k) clearances and European Union Medical Device Regulation certifications across its articulating device portfolio; and the successful completion of initial feasibility wet-lab demonstrations verifying long-distance telesurgical procedures using the STARK surgical robotic platform.